English    Română    Española   

Adn-388

ADN-388 follows the dramatic arc typical of the “Husband’s Boss” subgenre. The story centers on Misaki (played by the lead actress), a devoted wife whose husband faces intense pressure from his overbearing and unscrupulous boss. The boss discovers a weakness in the couple—usually financial or career-related—and leverages it to force Misaki into sexual compliance. The narrative explores her slow, psychological breakdown as she moves from vehement refusal to numb acceptance, and finally to conflicted complicity.

ADN‑388 is a bicyclic pyrrolopyrimidine derivative (C₁₈H₂₁N₅O₃) with a lipophilic side chain that enhances membrane permeability. The molecule’s core scaffold was optimized through a structure‑guided fragment‑based drug design (FBDD) campaign that leveraged high‑resolution crystal structures of RdRp from multiple viral families.

| Species | Dose (mg/kg) | Cmax (µg/mL) | t½ (h) | AUC₀‑∞ (µg·h/mL) | Oral Bioavailability | |---------|--------------|--------------|--------|------------------|----------------------| | Rat | 10 | 4.8 | 6.2 | 38.5 | 84% | | Dog | 5 | 3.2 | 7.4 | 31.1 | 78% | | Non‑human primate (cynomolgus) | 3 | 2.6 | 9.0 | 27.8 | 81% | ADN-388

ADN‑388 exhibits linear PK across the dose range, minimal food effect, and low plasma protein binding (≈12%). Metabolism is primarily via CYP3A4, generating a single inactive N‑oxide metabolite that is rapidly cleared renally.

The past two decades have underscored the global vulnerability to emerging RNA viruses. The rapid evolution of viral polymerases, combined with limited therapeutic options, has driven the need for broad‑acting antivirals that can be deployed quickly against novel pathogens. ADN‑388, discovered by Adept BioNexus (ADN) in 2023, represents a paradigm shift: a single molecule capable of inhibiting a conserved enzymatic pocket across multiple viral families. ADN-388 follows the dramatic arc typical of the

Key attributes that distinguish ADN‑388 from earlier antivirals include:

| Feature | ADN‑388 | Conventional Antivirals | |---------|--------|--------------------------| | Target | Conserved RdRp motif (Motif C) | Virus‑specific proteins (e.g., proteases, entry receptors) | | Spectrum | Broad (≥15 RNA virus families) | Narrow (typically 1–2 related viruses) | | Resistance Barrier | High (multiple simultaneous mutations required) | Low to moderate | | Oral Bioavailability | >80% (fasted) | Variable | | Safety Margin (LD₅₀/ED₅₀) | >10,000× | 100–1,000× | Interim Analysis (data cut‑off Jan 2026) – Overall

  • Interim Analysis (data cut‑off Jan 2026) – Overall risk reduction of 68% (95% CI 55‑77 %). No safety signals beyond mild gastrointestinal symptoms. The Data Safety Monitoring Board (DSMB) recommended continuation to full enrollment.

  • Regulatory Status – Fast‑track designation from FDA (2025), PRIME status from EMA (2025), and conditional approval for COVID‑19 treatment granted in the United States (Nov 2026) pending final Phase III data.

    • ADN‑388 is a next‑generation antiviral small‑molecule inhibitor that targets the conserved RNA‑dependent RNA polymerase (RdRp) of a broad spectrum of RNA viruses, including flaviviruses, coronaviruses, and paramyxoviruses. Early‑stage preclinical studies demonstrated potent nanomolar activity against SARS‑CoV‑2 variants, Zika virus, and Nipah virus, while maintaining an excellent safety profile in rodent and non‑human‑primate models. The compound entered Phase I clinical trials in early 2025 and progressed to a pivotal Phase II/III multicenter study in 2026. This article reviews the molecular design, mechanism of action, preclinical data, clinical development, and future prospects of ADN‑388 as a universal antiviral platform.

    Adn-388

    If you want to improve the layout you can modify it by moving, adding and deleting pieces. The following steps are required:

    Adn-388

    1 user, 1 computer 25 Euro

    Try before you buy. There is no money-back option after payment confirmation!



    Buy Now buy now Simple Cutting Software X

    You will be redirected to our distributor and payment processor.

    If you are a company from the European Union and have a valid VAT number, you may pay directly to us (by bank transfer only).
    In this case, send us an email with the data for the invoicing (including EU VAT number).

    Registration key is sent by email only.

    Please check the Spam folder if you have not received the key in several minutes after payment confirmation.

    Free for schools, colleges and universities (for educational purposes)! Please apply here for a free educational license.

    Adn-388

    Adn-388

    Want more features ? Try our Cutting Optimization pro for rectangular optimization or Next Nesting Software X for any shape (polygons and circles) optimization. A list of features for each software is given here: Compare software.

    Adn-388

    Email (primary):contact@nesting-technologies.com

    Email (less utilized):nesting.tech@gmail.com

    If you don't receive an answer from us in 48 hours it means that your email provider blocks our email address.!

    In this case please send us an email from an gmail or yahoo address !

    nesting-technologies.com